Haemonetics Corporation

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Haemonetics Corporation sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 10 completed early-phase tilt top decile by trial count

Haemonetics Corporation: 11 sponsored US clinical trials, none currently recruiting.

Haemonetics Corporation sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Transmission, Blood, Recipient/Donor, with 1 trials.

Top-decile sponsor footprint

Haemonetics Corporation ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 67/100

10 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED

An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge

NCT06352125
COMPLETED

Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers

NCT06261580
COMPLETED NA

IMPACT (Improving Plasma Collection) Clinical Trial

NCT04320823
COMPLETED

Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System

NCT02798328
COMPLETED NA

Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder

NCT02476851
COMPLETED

Procedure For The Reference Range Study For Absolute MA

NCT02110576
COMPLETED Phase 1

Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution

NCT02145507
COMPLETED

Clinical Investigational Protocol for 2 RBC Single Unit Recovery on MCS®+ 8150 Using LN832 Disposable Sets (US)

NCT01764061
COMPLETED

Clinical Evaluation of the OrthoPAT Advance System

NCT01756976
TERMINATED

RapidTEG MA Validation

NCT01428102
COMPLETED

Thromboelastography (TEG) Reference Range Study

NCT01357928

Phase Distribution

PhaseTrial count
Phase 1 1

Therapeutic Areas

Transmission, Blood, Recipient/Donor 1
Apheresis Related Hypotension 1
Healthy 1

How the Haemonetics Corporation early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 10 completed (91%).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Transmission, Blood, Recipient/Donor (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Haemonetics Corporation: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Haemonetics Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Haemonetics CorporationAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Haemonetics Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Haemonetics Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Haemonetics Corporation page

11 registered trials is a research-attention snapshot, not an endorsement of Haemonetics Corporation or any single study.

  • None of Haemonetics Corporation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Transmission, Blood, Recipient/Donor is the condition Haemonetics Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Transmission, Blood, Recipient/Donor trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Haemonetics Corporation pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.